CU20130080A7 - Derivados bicíclicos sustituidos para el tratamiento del sida - Google Patents

Derivados bicíclicos sustituidos para el tratamiento del sida

Info

Publication number
CU20130080A7
CU20130080A7 CUP2013000080A CU20130080A CU20130080A7 CU 20130080 A7 CU20130080 A7 CU 20130080A7 CU P2013000080 A CUP2013000080 A CU P2013000080A CU 20130080 A CU20130080 A CU 20130080A CU 20130080 A7 CU20130080 A7 CU 20130080A7
Authority
CU
Cuba
Prior art keywords
group
nra
nrarb
hydrogen atom
aids
Prior art date
Application number
CUP2013000080A
Other languages
English (en)
Inventor
Jamal Tazi
Florence Mahuteau
Romain Najman
Didier Scherrer
Noëlie Campos
Aude Garcel
Original Assignee
Centre Nat Rech Scient
Inst Curie
Univ Montpellier 2
Abivax
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Inst Curie, Univ Montpellier 2, Abivax filed Critical Centre Nat Rech Scient
Publication of CU20130080A7 publication Critical patent/CU20130080A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a un compuesto de fórmula (I) para uso como un agente que previene, inhibe o trata el SIDA. La presente invención además se refiere a compuestos de fórmula (I), en donde: X es CR0, o N; R0, R1, R2, R3, R4, R7 y R8 representan independientemente un átomo de hidrógeno, un átomo de halógeno o un grupo elegido entre un grupo alquilo (C1-C5), un grupo cicloalquilo (C3-C6), un grupo fluoroalquilo (C1-C5), un grupo alcoxi (C1-C5), un grupo fluoroalcoxi (C1-C5), un grupo -CN, un grupo -COORa, un grupo -NO2, un grupo -NRaRb, un grupo -NRa-SO2-NRaRb, un grupo -NRa- SO2-Ra, un grupo -NRa-C(=O)- Ra, un grupo -NRa-C (=O)-NRaRb, un grupo -SO2-NRaRb, un grupo -SO3H, un grupo -OH, un grupo -O-SO2-ORc, un grupo -0-P(=O)- (ORc) (ORd), un grupo - O-CH2-COORc y puede ser además un grupo elegido entre: (IIa), (IIIa), R5 representa un átomo de hidrógeno, un grupo alquilo (C1-C5) o un grupo cicloalquilo (C3-C6); R10 es un átomo de hidrógeno o un átomo de cloro, y R11 es un átomo de hidrógeno o un grupo alquilo (C1-C4), o cualquiera de sus sales farmacéuticamente aceptables, donde dicha sal es hidroclorido.
CUP2013000080A 2010-12-15 2013-06-13 Derivados bicíclicos sustituidos para el tratamiento del sida CU20130080A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10306417A EP2465502A1 (en) 2010-12-15 2010-12-15 Compounds useful for treating AIDS
PCT/IB2011/055643 WO2012080953A1 (en) 2010-12-15 2011-12-13 Compounds useful for treating aids

Publications (1)

Publication Number Publication Date
CU20130080A7 true CU20130080A7 (es) 2013-08-29

Family

ID=43755105

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2013000080A CU20130080A7 (es) 2010-12-15 2013-06-13 Derivados bicíclicos sustituidos para el tratamiento del sida

Country Status (19)

Country Link
US (1) US9061999B2 (es)
EP (2) EP2465502A1 (es)
JP (1) JP6049630B2 (es)
KR (1) KR101749232B1 (es)
CN (1) CN103415290B (es)
AR (1) AR084277A1 (es)
AU (1) AU2011342826B2 (es)
BR (1) BR112013014943B1 (es)
CA (1) CA2819317C (es)
CU (1) CU20130080A7 (es)
DK (1) DK2651416T3 (es)
ES (1) ES2681539T3 (es)
HR (1) HRP20181190T1 (es)
MX (1) MX337258B (es)
PL (1) PL2651416T3 (es)
PT (1) PT2651416T (es)
RU (1) RU2598845C2 (es)
WO (1) WO2012080953A1 (es)
ZA (1) ZA201303922B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010143169A2 (en) 2009-06-12 2010-12-16 Société Splicos Compounds useful for treating aids
US10253020B2 (en) 2009-06-12 2019-04-09 Abivax Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging
EP2757161A1 (en) 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
AU2014285733B2 (en) * 2013-07-05 2019-05-16 Abivax Bicyclic compounds useful for treating diseases caused by retroviruses
EP2975034A1 (en) * 2014-07-17 2016-01-20 Abivax A quinoline derivative for the treatment of inflammatory diseases and AIDS
EP2974729A1 (en) * 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
EP3059591A1 (en) * 2015-02-23 2016-08-24 Abivax Methods for screening compounds for treating or preventing a viral infection or a virus-related condition
EP3058940A1 (en) * 2015-02-23 2016-08-24 Abivax Quinoline derivatives for use in the treatment or prevention of viral infection
EP3059236A1 (en) 2015-02-23 2016-08-24 Abivax A new quinoline derivative for use in the treatment and prevention of viral infections
WO2017034986A1 (en) * 2015-08-21 2017-03-02 University Of Kansas Human tlr8-selective agonists
ES2899926T3 (es) * 2016-03-18 2022-03-15 Prosynergia S A R L Procedimiento para preparar derivados de quinolin-2-il-fenilamina y sus sales
KR101966351B1 (ko) * 2016-06-08 2019-04-08 한국과학기술연구원 히스톤 메틸전달효소 저해용 퀴놀린 유도체 및 이의 용도
US10323289B2 (en) 2017-06-26 2019-06-18 Institut Pasteur Treatments to eliminate HIV reservoirs and reduce viral load
WO2019186277A1 (en) 2018-03-28 2019-10-03 Institut Pasteur Ultrasensitive hiv-1 p24 detection assay
EP3594205A1 (en) 2018-07-09 2020-01-15 Abivax Phenyl-n-aryl derivatives for treating a rna virus infection
EP3594206A1 (en) * 2018-07-09 2020-01-15 Abivax Phenyl-n-quinoline derivatives for treating a rna virus infection
EP3669873A1 (en) 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use ine the traeatment of inflammation diseases
EP3669874A1 (en) 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use in the treatment or prevention of cancer
WO2020128033A1 (en) 2018-12-20 2020-06-25 Institut Pasteur Cellular metabolism of hiv-1 reservoir seeding in cd4+ t cells
CN109776498B (zh) * 2019-03-13 2020-04-07 浙江永宁药业股份有限公司 一种西洛他唑的制备方法
EP4063351A1 (en) * 2021-03-26 2022-09-28 Abivax Preparation method of quinoline derivative compounds
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator
EP4215196A1 (en) 2022-01-24 2023-07-26 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a jak inhibitor

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2419199A (en) * 1945-02-09 1947-04-22 Parke Davis & Co Quinoline compounds and process of making same
FR2387229A1 (fr) 1977-04-13 1978-11-10 Anvar Dipyrido (4,3-b) (3,4-f) indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant
FR2436786A1 (fr) 1978-09-21 1980-04-18 Anvar Nouveaux derives des pyrido (4,3-b) carbazoles (ellipticines), substitues en position 1 par une chaine polyaminee, leur obtention et leur application a titre de medicaments
US4466965A (en) * 1982-07-26 1984-08-21 American Hospital Supply Corporation Phthalazine compounds, compositions and use
JPS59501318A (ja) * 1982-07-26 1984-07-26 アメリカン　ホスピタル　サプライ　コ−ポレ−シヨン ヘテロアリ−ル置換アミノメチルベンゼン誘導体
FR2627493B1 (fr) 1988-02-23 1991-10-31 Sanofi Sa Procede de preparation de derives d'isoquinoleine
FR2645861A1 (fr) 1989-04-17 1990-10-19 Inst Nat Sante Rech Med Utilisation de dipyrido (4,3-b) (3,4-f) indoles pour la preparation de medicaments utiles pour le traitement du sida
US6337350B1 (en) 1999-04-05 2002-01-08 City Of Hope Inhibitors of formation of advanced glycation endproducts (AGEs)
UA75055C2 (uk) * 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
EP1542692B1 (en) 2002-05-22 2011-01-05 Amgen Inc. Aminopyrimidine derivatives for use as vanilloid receptor ligands for the treatment of pain
AU2002950217A0 (en) * 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
WO2004009552A1 (en) 2002-07-19 2004-01-29 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
FR2849474B3 (fr) 2002-12-27 2004-12-03 Olivier Jean Noel Juin Installation de transformation de l'energie cinetique d'un fluide en energie electrique
WO2004078731A1 (fr) * 2003-03-06 2004-09-16 'chemical Diversity Research Institute', Ltd. Acides quinoline-carboxyliques et leurs derives et bibliotheque focalisee
FR2859474B1 (fr) 2003-09-04 2006-01-13 Centre Nat Rech Scient Utilisation de composes derives d'indole pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage
FR2859475A1 (fr) 2003-09-04 2005-03-11 Centre Nat Rech Scient Utilisation de composes derives d'ellipticine et d'aza-ellipticine pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage
EP1853265B1 (en) 2005-01-28 2016-01-27 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Farnesyltransferase inhibitors for use in the treatment of laminopathies, cellular aging and atherosclerosis
FR2903312B1 (fr) 2006-07-05 2008-09-26 Univ Aix Marseille Ii Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
US8030487B2 (en) 2006-07-07 2011-10-04 Targegen, Inc. 2-amino—5-substituted pyrimidine inhibitors
FR2912745A1 (fr) 2007-02-19 2008-08-22 Centre Nat Rech Scient Nouveaux composes derives d'indole et compositions pharmaceutiques les contenant
US20100249184A1 (en) 2007-03-16 2010-09-30 Mount Sinai School Of Medicine Induction and/or maintenance of tumor dormancy by disruption of urokinase plasminogen activator receptor-integrin interaction
CN101679150B (zh) 2007-05-17 2013-05-15 Lg化学株式会社 蒽衍生物和使用该蒽衍生物的有机电子器件
AU2008286760A1 (en) 2007-08-15 2009-02-19 Memory Pharmaceuticals Corporation 3' substituted compounds having 5-HT6 receptor affinity
FR2926297B1 (fr) 2008-01-10 2013-03-08 Centre Nat Rech Scient Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage.
WO2010143169A2 (en) 2009-06-12 2010-12-16 Société Splicos Compounds useful for treating aids

Also Published As

Publication number Publication date
JP6049630B2 (ja) 2016-12-21
EP2651416A1 (en) 2013-10-23
WO2012080953A1 (en) 2012-06-21
ES2681539T3 (es) 2018-09-13
DK2651416T3 (en) 2018-08-06
US9061999B2 (en) 2015-06-23
MX2013006322A (es) 2013-10-25
EP2651416B1 (en) 2018-05-09
CA2819317A1 (en) 2012-06-21
CA2819317C (en) 2017-02-28
KR101749232B1 (ko) 2017-07-03
JP2013545798A (ja) 2013-12-26
AR084277A1 (es) 2013-05-02
AU2011342826B2 (en) 2016-02-11
AU2011342826A1 (en) 2013-07-04
CN103415290A (zh) 2013-11-27
EP2465502A1 (en) 2012-06-20
KR20140041402A (ko) 2014-04-04
BR112013014943A8 (pt) 2018-06-12
PL2651416T3 (pl) 2018-09-28
PT2651416T (pt) 2018-07-30
RU2598845C2 (ru) 2016-09-27
HRP20181190T1 (hr) 2019-03-08
CN103415290B (zh) 2016-09-14
RU2013126947A (ru) 2015-01-20
MX337258B (es) 2016-02-22
ZA201303922B (en) 2014-07-30
BR112013014943B1 (pt) 2022-05-03
US20130267703A1 (en) 2013-10-10
BR112013014943A2 (pt) 2016-09-13

Similar Documents

Publication Publication Date Title
CU20130080A7 (es) Derivados bicíclicos sustituidos para el tratamiento del sida
CL2019000512A1 (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica.
AR077975A1 (es) Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
CR20150509A (es) Derivados de naftiridina utiles como antagonistas de la alfa-v-beta-6 integrina
AR098912A1 (es) Inhibidores de syk
UY36101A (es) Herbicidas de piridazinona
CR20170118A (es) Derivados espirodiamina como inhibidores de la aldosterona sintasa
AR097024A1 (es) Derivados sustituidos de quinazolin-4-ona
AR081859A1 (es) Pirimidinas 2,4,6-trisustituidas, composiciones farmaceuticas que las comprenden y su uso en el tratamiento de tumores sensibles a la inhibicion de la cinasa atr
CO6160326A2 (es) Derivados de pirrolidin-2-ona como moduladores del receptor de androgeno
PE20160524A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
ES2669189T3 (es) Compuestos de carbazol útiles como inhibidores del bromodominio
ES2637167T3 (es) Compuestos de tetrahidro-pirido-piridina y tetrahidro-pirido-pirimidina y su uso como moduladores de los receptores de C5a
AR099379A1 (es) Compuestos tricíclicos como agentes antineoplásicos
AR088692A1 (es) Derivados de 2-(1,2,3-triazol-2-il)benzamina y 3-(1,2,3-triazol-2-il)picolinamida
AR117916A1 (es) Compuesto heterocíclico y su uso
UY34451A (es) Derivados de uracilo como inhibidores de la quinasa axl y c-met
PE20121048A1 (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
AR072224A1 (es) Derivados de pirimidona sustituidos
AR088226A1 (es) Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas
AR062409A1 (es) Compuesto y composicion farmaceutica, utiles como agentes terapeuticos en el tratamiento, prevencion o mejoramiento de enfermedad o trastorno caracterizado por depositos o niveles de b-amiloide elevados o para inhibir o elucidar la enzima b-secretasa, y proceso para la preparacion del compuesto
ECSP11011201A (es) Combinaciones que comprenden metotrexato e inhibidores de dhodh
MX2017000533A (es) Derivados de quinoleina para el tratamiento de enfermedades inflamatorias.
ECSP11011318A (es) Derivados de benzofurano
CR20150378A (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas